The product has recently been introduced under the brand Accofil and has already won two tenders, in Netherlands and the UK
Intas Pharmaceuticals has launched their first biosimilar, filgrastim, in Europe, through their wholly-owned subsidiary Accord Healthcare. The product has recently been introduced under the brand Accofil and has already won two tenders, in Netherlands and the UK respectively. In addition, Intas is also the only company from India to have two of its products, filgrastim and peg-filgrastim filed for registration in the US, through its collaboration partner.
According to the company release, Accofil is a biosimilar product of Neupogen (filgrastim) and will offer patients cost effective therapy that is comparable in quality, safety and efficacy. Accofil is indicated for the treatment of reduction in the duration of neutropenia and the incidence of febrile neutropenia, mobilisation of peripheral blood progenitor cells, severe congenital, cyclic, or idiopathic neutropenia and persistent neutropenia in patients with advanced HIV infection.
Binish Chudgar, Vice-Chairman, Intas Pharmaceuticals said, “The launch of our filgrastim in Europe is another demonstration of our commitment to global healthcare at affordable prices. Accofil (filgrastim), which was developed at our own laboratories and manufactured at our own cGMP approved site in Ahmedabad, showcases our expertise in biopharmaceutical development and its manufacture. This is only the first of many biological products that we will launch in EU and other regulated markets over the next few years.”